Your browser doesn't support javascript.
loading
Loss of Hepatic Leucine-Rich Repeat-Containing G-Protein Coupled Receptors 4 and 5 Promotes Nonalcoholic Fatty Liver Disease.
Saponara, Enrica; Penno, Carlos; Orsini, Vanessa; Wang, Zhong-Yi; Fischer, Audrey; Aebi, Alexandra; Matadamas-Guzman, Meztli L; Brun, Virginie; Fischer, Benoit; Brousseau, Margaret; O'Donnell, Peter; Turner, Jonathan; Graff Meyer, Alexandra; Bollepalli, Laura; d'Ario, Giovanni; Roma, Guglielmo; Carbone, Walter; Annunziato, Stefano; Obrecht, Michael; Beckmann, Nicolau; Saravanan, Chandra; Osmont, Arnaud; Tropberger, Philipp; Richards, Shola M; Genoud, Christel; Ley, Svenja; Ksiazek, Iwona; Nigsch, Florian; Terracciano, Luigi M; Schadt, Heiko S; Bouwmeester, Tewis; Tchorz, Jan S; Ruffner, Heinz.
Afiliação
  • Saponara E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Penno C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Orsini V; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Wang ZY; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Fischer A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Aebi A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Matadamas-Guzman ML; Instituto Nacional de Medicina Genómica-Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Brun V; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Fischer B; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Brousseau M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, Massachusetts.
  • O'Donnell P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, Massachusetts.
  • Turner J; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Graff Meyer A; Friedrich Miescher Institute for BioMedical Research, Facility for Advanced Imaging and Microscopy, Basel, Switzerland.
  • Bollepalli L; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • d'Ario G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Roma G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Carbone W; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Annunziato S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Obrecht M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Beckmann N; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Saravanan C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, Massachusetts.
  • Osmont A; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Tropberger P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Richards SM; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Genoud C; Electron Microscopy Facility, University of Lausanne, Lausanne, Switzerland.
  • Ley S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Ksiazek I; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Nigsch F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Terracciano LM; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Istituto di Ricovero e Cura a Carattere Scientifico, Humanitas Research Hospital, Anatomia Patologica, Rozzano, Milan, Italy.
  • Schadt HS; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Bouwmeester T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Tchorz JS; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Ruffner H; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: heinz.ruffner@novartis.com.
Am J Pathol ; 193(2): 161-181, 2023 02.
Article em En | MEDLINE | ID: mdl-36410420
ABSTRACT
The roof plate-specific spondin-leucine-rich repeat-containing G-protein coupled receptor 4/5 (LGR4/5)-zinc and ring finger 3 (ZNRF3)/ring finger protein 43 (RNF43) module is a master regulator of hepatic Wnt/ß-catenin signaling and metabolic zonation. However, its impact on nonalcoholic fatty liver disease (NAFLD) remains unclear. The current study investigated whether hepatic epithelial cell-specific loss of the Wnt/ß-catenin modulator Lgr4/5 promoted NAFLD. The 3- and 6-month-old mice with hepatic epithelial cell-specific deletion of both receptors Lgr4/5 (Lgr4/5dLKO) were compared with control mice fed with normal diet (ND) or high-fat diet (HFD). Six-month-old HFD-fed Lgr4/5dLKO mice developed hepatic steatosis and fibrosis but the control mice did not. Serum cholesterol-high-density lipoprotein and total cholesterol levels in 3- and 6-month-old HFD-fed Lgr4/5dLKO mice were decreased compared with those in control mice. An ex vivo primary hepatocyte culture assay and a comprehensive bile acid (BA) characterization in liver, plasma, bile, and feces demonstrated that ND-fed Lgr4/5dLKO mice had impaired BA secretion, predisposing them to develop cholestatic characteristics. Lipidome and RNA-sequencing analyses demonstrated severe alterations in several lipid species and pathways controlling lipid metabolism in the livers of Lgr4/5dLKO mice. In conclusion, loss of hepatic Wnt/ß-catenin activity by Lgr4/5 deletion led to loss of BA secretion, cholestatic features, altered lipid homeostasis, and deregulation of lipoprotein pathways. Both BA and intrinsic lipid alterations contributed to the onset of NAFLD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça